Cytokinetics Announces Upcoming Presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific Meeting
Cytokinetics (Nasdaq: CYTK) announced upcoming presentations at two major cardiology conferences in Atlanta, GA. At the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions on September 27, 2024, three presentations will focus on:
- Global remodeling changes with aficamten in obstructive hypertrophic cardiomyopathy patients
- Efficacy and safety of aficamten in patients with very high left ventricular outflow tract gradients
- Beta-blocker use and new atrial fibrillation in post-septal myectomy patients
Additionally, at the Heart Failure Society of America (HFSA) Annual Scientific Meeting on September 30, 2024, a Late Breaking Clinical Trial presentation will discuss the global clinical impact of aficamten in obstructive hypertrophic cardiomyopathy, based on results from the SEQUOIA-HCM trial. These presentations highlight Cytokinetics' ongoing research in cardiac treatments, particularly focusing on aficamten's effects in hypertrophic cardiomyopathy patients.
Cytokinetics (Nasdaq: CYTK) ha annunciato presentazioni imminenti in due importanti conferenze di cardiologia ad Atlanta, GA. Durante le Sessioni Scientifiche della Hypertrophic Cardiomyopathy Medical Society (HCMS) il 27 settembre 2024, tre presentazioni si concentreranno su:
- Cambiamenti globali di rimodellamento con aficamten nei pazienti con cardiomiopatia ipertrofica ostruttiva
- Efficacia e sicurezza di aficamten in pazienti con gradienti del tratto di efflusso ventricolare sinistro molto elevati
- Uso di beta-bloccanti e nuova fibrillazione atriale nei pazienti sottoposti a miotomia post-settale
Inoltre, durante la Conferenza Scientifica Annuale della Heart Failure Society of America (HFSA) il 30 settembre 2024, una presentazione su un Trial Clinico di Impatto Ritardato discuterà dell'impatto clinico globale di aficamten nella cardiomiopatia ipertrofica ostruttiva, basandosi sui risultati del trial SEQUOIA-HCM. Queste presentazioni evidenziano la continua ricerca di Cytokinetics nei trattamenti cardiaci, con particolare attenzione agli effetti di aficamten nei pazienti con cardiomiopatia ipertrofica.
Cytokinetics (Nasdaq: CYTK) anunció presentaciones inminentes en dos importantes conferencias de cardiología en Atlanta, GA. En las Sesiones Científicas de la Hypertrophic Cardiomyopathy Medical Society (HCMS) el 27 de septiembre de 2024, tres presentaciones se centrarán en:
- Cambios globales de remodelación con aficamten en pacientes con cardiomiopatía hipetrofica obstructiva
- Eficacia y seguridad de aficamten en pacientes con gradientes muy altos en el tracto de salida del ventrículo izquierdo
- Uso de beta-bloqueantes y nueva fibrilación auricular en pacientes sometidos a miectomía post-septal
Además, en la Reunión Científica Anual de la Heart Failure Society of America (HFSA) el 30 de septiembre de 2024, una presentación de un Ensayo Clínico de Nueva Impacto discutirá el impacto clínico global de aficamten en la cardiomiopatía hipetrofica obstructiva, basado en los resultados del ensayo SEQUOIA-HCM. Estas presentaciones destacan la investigación continua de Cytokinetics en tratamientos cardíacos, centrándose particularmente en los efectos de aficamten en pacientes con cardiomiopatía hipetrofica.
Cytokinetics (Nasdaq: CYTK)는 조지아주 애틀랜타에서 열리는 두 개의 주요 심장학 컨퍼런스에서 예정된 발표를 발표했습니다. 2024년 9월 27일 비대심근병의학회 (HCMS) 과학 세션에서는 세 가지 발표가 다음에 중점을 둘 것입니다:
- 비대심근병 환자에서 aficamten에 의한 전세계적인 재구성 변화
- 왼쪽 심실 유출관 경도 매우 높은 환자에서 aficamten의 효능과 안전성
- 좌심실 중격 절제술 후 환자에서의 베타 차단제 사용 및 새로운 심방 세동
추가로, 2024년 9월 30일 미국심부전학회 (HFSA) 연례 과학 회의에서 늦은 임상 시험 발표가 obstructive hypertrophic cardiomyopathy에서 aficamten의 글로벌 임상 영향을 논의할 예정입니다. 이는 SEQUOIA-HCM 시험 결과를 기반으로 합니다. 이러한 발표는 비대 심근병 환자에서 aficamten의 효과에 특히 중점을 두고 있는 Cytokinetics의 심장 치료 연구를 강조합니다.
Cytokinetics (Nasdaq: CYTK) a annoncé des présentations à venir lors de deux grandes conférences de cardiologie à Atlanta, GA. Lors des Séances Scientifiques de la Hypertrophic Cardiomyopathy Medical Society (HCMS) le 27 septembre 2024, trois présentations se concentreront sur :
- Les changements de remodelage global avec aficamten chez les patients atteints de cardiomyopathie hypertrophique obstructive
- Efficacité et sécurité de l'aficamten chez les patients présentant des gradients très élevés au niveau du tractus de sortie du ventricule gauche
- Utilisation de bêta-bloquants et nouvelle fibrillation auriculaire chez les patients après myectomie septale
De plus, lors de la Réunion Scientifique Annuelle de la Heart Failure Society of America (HFSA) le 30 septembre 2024, une présentation sur un essai clinique de dernière minute discutera de l'impact clinique global de l'aficamten dans la cardiomyopathie hypertrophique obstructive, basé sur les résultats de l'essai SEQUOIA-HCM. Ces présentations mettent en avant la recherche continue de Cytokinetics dans les traitements cardiaques, en mettant particulièrement l'accent sur les effets de l'aficamten chez les patients souffrant de cardiomyopathie hypertrophique.
Cytokinetics (Nasdaq: CYTK) gab bekannt, dass sie an zwei wichtigen Kardiologie-Konferenzen in Atlanta, GA, präsentieren werden. Bei den Wissenschaftlichen Sitzungen der Hypertrophic Cardiomyopathy Medical Society (HCMS) am 27. September 2024 werden sich drei Präsentationen auf Folgendes konzentrieren:
- Globale Umstrukturierungsänderungen mit aficamten bei Patienten mit obstruktiver hypertropher Kardiomyopathie
- Wirksamkeit und Sicherheit von aficamten bei Patienten mit sehr hohen Gradienten im linken Ventrikelausflussweg
- Beta-Blocker-Einsatz und neue Vorhofflimmern bei Patienten nach septaler Myektomie
Zusätzlich wird bei der Jahrestagung der Heart Failure Society of America (HFSA) am 30. September 2024 eine späte klinische Studienpräsentation die globale klinische Auswirkung von aficamten bei obstruktiver hypertropher Kardiomyopathie erörtern, basierend auf den Ergebnissen der SEQUOIA-HCM-Studie. Diese Präsentationen heben die fortlaufende Forschung von Cytokinetics in der kardiologischen Behandlung hervor, insbesondere die Auswirkungen von aficamten bei Patienten mit hypertropher Kardiomyopathie.
- None.
- None.
Analyses of Effects of Aficamten on Key Clinical Outcomes from SEQUOIA-HCM to be Featured in Late Breaking Clinical Trial Presentation at HFSA
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three upcoming presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions on September 27, 2024 and one Late Breaking Clinical Trial presentation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting, taking place September 27-30, 2024, both in Atlanta, GA.
2024 HCMS Scientific Sessions
Oral Abstract Presentation
Title: Global Remodeling Changes with Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy: An Analysis of the SEQUOIA-HCM Trial
Presenter: Anjali T. Owens, M.D., Medical Director, Center for Inherited Cardiac Disease, Assistant Professor of Medicine, University of Pennsylvania
Date: September 27, 2024
Session Title: Oral Abstract Presentations
Session Time: 11:00 – 12:00 PM ET
Location: Signia by Hilton, Atlanta Georgia World Congress Center
Poster Abstract Presentation
Title: Efficacy and Safety of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Very High Left Ventricular Outflow Tract Gradients
Presenter: Juan R. Gimeno, M.D., Consultant Cardiologist, Hospital Universitario Virgen de la Arrixaca, Associate Professor, Medicine – Cardiology, Universidad de Murcia, Spain
Date: September 27, 2024
Session Title: Closing Remarks & Poster Cocktail Reception
Session Time: 4:00 – 5:00 PM ET
Location: Signia by Hilton, Atlanta Georgia World Congress Center
Title: Beta-Blocker Use and Incidence of New Atrial Fibrillation or Flutter Requiring Therapy in Post-Septal Myectomy Hypertrophic Cardiomyopathy Patients
Presenter: Morris M. Kim, M.D., Cardiovascular Disease Fellow, Oregon Health & Science University
Date: September 27, 2024
Session Title: Closing Remarks & Poster Cocktail Reception
Session Time: 4:00 – 5:00 PM ET
Location: Signia by Hilton, Atlanta Georgia World Congress Center
HFSA Annual Scientific Meeting
Title: Global Clinical Impact of Aficamten in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM
Presenter: Martin Maron, M.D., Director, Hypertrophic Cardiomyopathy Center, Lahey Hospital and Medical Center
Date: September 30, 2024
Session Title: Plenary Sessions - Monday Plenary Session: Late Breaking Clinical Research Session II
Session Time: 9:00 – 10:30 AM ET
Presentation Time: 9:20 – 9:28 AM ET
Location: Georgia World Congress Center - Georgia Ballroom 2
About Cytokinetics
Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive hypertrophic cardiomyopathy which were published in the New England Journal of Medicine. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
FAQ
What are the key presentations for Cytokinetics (CYTK) at the HCMS Scientific Sessions on September 27, 2024?
What is the focus of Cytokinetics' (CYTK) Late Breaking Clinical Trial presentation at the HFSA Annual Scientific Meeting on September 30, 2024?
Where and when will Cytokinetics (CYTK) present its research on aficamten in hypertrophic cardiomyopathy?
What specific patient groups are addressed in Cytokinetics' (CYTK) upcoming presentations?
